

## References

I-28

1. Blair H A, Deeks E D. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. *BioDrugs*. 2016;469–480.
2. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Infliximab.
3. Remicade® (Infliximab) [package insert]. Jansen Biotech, Inc. Horsham, PA. 05/2020.
4. INFLECTRA (infliximab-dyyb) [package insert]. Lake Forest, IL. Jansen Pfizer Company. 08/2020.
5. RENFLEXIS (infliximab-abda) [package insert]. Kenilworth, NJ. Merck Sharp & Dohme Corp. 10/2019.
6. Condino AA, Fidanza S, Hoffenburg EJ. A home infliximab infusion program. *NHS*. 2005;67-69.
7. Barfield E, Solomon A, Sockolow R. Infliximab in the Home – Does it Affect the Health-Related Quality of Life of Pediatric Patients with Inflammatory Bowel Disease? *Practical Gastro*. 2016;16-
8. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
9. Giancane G, Consolaro A, Lanni S, et al. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. *Rheumatol Ther*. 2016;3(2):187-207.
10. Lichtenstein G, Loftus E, Isaacs K, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113:481–517.
11. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*. 2011;70:896– 904.
12. Ringold S, Weiss P, Colbert R, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. *Arthritis Care Res*. 2014;66(7):1063-1072.
13. Menter A, Gottlieb A, Feldman S, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2018;58(5):826-850.
14. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. 2019;156(5):1508-1524.
15. Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-1072.

16. Singh J, Saag K, Bridges Jr S, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res.* 2015;68(1):1-25.
17. Rubin D, Snanthakrishnan A, Siegel C, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol.* 2019;114:384-413
18. Avsola™ (infliximab-axxq), for injection, for intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. 2019. Revised 12/2019.
19. Tajiri H, Arai K, Kagimoto S, et al. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. *BMC Pediatrics.* 2019;19:351.
20. Goll G, Jorgensen K, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. *J Intern Med.* 2019;285:653-669.
21. Infliximab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2020.
22. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.
23. Micromedex DrugDex Compendium®. 2020. Infliximab.